{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:15:45Z","timestamp":1791486945052,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To define resistant hypertension (RHT), review its pathophysiology and disease burden, identify barriers to effective hypertension management, and to highlight emerging treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>RHT is defined as uncontrolled blood pressure (BP)\u2009\u2265\u2009130\/80\u00a0mm Hg despite concurrent prescription of\u2009\u2265\u20093 or\u2009\u2265\u20094 antihypertensive drugs in different classes or controlled BP despite prescription of\u2009 \u2265 to 4 drugs, at maximally tolerated doses, including a diuretic. BP is regulated by a complex interplay between the renin\u2013angiotensin\u2013aldosterone system, the sympathetic nervous system, the endothelin system, natriuretic peptides, the arterial vasculature, and the immune system; disruption of any of these can increase BP. RHT is disproportionately manifest in African Americans, older patients, and those with diabetes and\/or chronic kidney disease (CKD). Amongst drug-treated hypertensives, only one-quarter have been treated intensively enough (prescribed\u2009&gt;\u20092 drugs) to be considered for this diagnosis. New treatment strategies aimed at novel therapeutic targets include inhibition of sodium-glucose cotransporter 2, aminopeptidase A, aldosterone synthesis, phosphodiesterase 5, xanthine oxidase, and dopamine beta-hydroxylase, as well as soluble guanylate cyclase stimulation, nonsteroidal mineralocorticoid receptor antagonism, and dual endothelin receptor antagonism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The burden of RHT remains high. Better use of currently approved therapies and integrating emerging therapies are welcome additions to the therapeutic armamentarium for addressing needs in high-risk aTRH patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11906-023-01282-0","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T01:02:33Z","timestamp":1708045353000},"page":"183-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Resistant Hypertension: Disease Burden and Emerging Treatment Options"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-5598","authenticated-orcid":false,"given":"John M.","family":"Flack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5996-8927","authenticated-orcid":false,"given":"Michael G.","family":"Buhnerkempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-102X","authenticated-orcid":false,"given":"Kenneth Todd","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"1282_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). Million Hearts. Estimated hypertension prevalence, treatment, and control among U.S. adults. March 22, 2021. https:\/\/millionhearts.hhs.gov\/data-reports\/hypertension-prevalence.html Accessed Oct 21, 2022."},{"issue":"9455","key":"1282_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(05)17741-1.","journal-title":"Lancet"},{"issue":"5","key":"1282_CR3","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53\u201390. https:\/\/doi.org\/10.1161\/HYP.0000000000000084.","journal-title":"Hypertension"},{"issue":"7","key":"1282_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","volume":"124","author":"M Burnier","year":"2019","unstructured":"Burnier M, Egan BM. Adherence in hypertension: a review of prevalence, risk factors, impact, and management. Circ Res. 2019;124(7):1124\u201340. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313220.","journal-title":"Circ Res"},{"issue":"5","key":"1282_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cjca.2015.06.033","volume":"32","author":"M Siddiqui","year":"2016","unstructured":"Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol. 2016;32(5):603\u20136. https:\/\/doi.org\/10.1016\/j.cjca.2015.06.033.","journal-title":"Can J Cardiol"},{"issue":"9","key":"1282_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HJH.0000000000002103","volume":"37","author":"MG Buhnerkempe","year":"2019","unstructured":"Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019;37(9):1797\u2013804. https:\/\/doi.org\/10.1097\/HJH.0000000000002103.","journal-title":"J Hypertens"},{"issue":"7","key":"1282_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","volume":"124","author":"MC Acelajado","year":"2019","unstructured":"Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019;124(7):1061\u201370. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312156.","journal-title":"Circ Res"},{"key":"1282_CR8","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Buhnerkempe MG, Prakash V, Botchway A, Adekola B, Cohen JB, Rahman M, et al. Adverse health outcomes associated with refractory and treatment-resistant hypertension in the chronic renal insufficiency cohort. Hypertension. 2021;77(1):72\u201381. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15064. This study demonstrated the longitudinal risk for adverse health outcomes in patients with refractory, resistant, and non-refractory or resistant hypertension and chronic kidney disease.","DOI":"10.1161\/HYPERTENSIONAHA.120.15064"},{"issue":"6","key":"1282_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/hr.2013.30","volume":"36","author":"ML Muiesan","year":"2013","unstructured":"Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C, et al. Resistant hypertension and target organ damage. Hypertens Res. 2013;36(6):485\u201391. https:\/\/doi.org\/10.1038\/hr.2013.30.","journal-title":"Hypertens Res"},{"key":"1282_CR10","doi-asserted-by":"publisher","unstructured":"Cepeda M, Pham P, Shimbo D. Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of hypertension in the US: an up-to-date review. Hypertens Res. 2023:1\u201310. https:\/\/doi.org\/10.1038\/s41440-022-01137-2.","DOI":"10.1038\/s41440-022-01137-2"},{"key":"1282_CR11","unstructured":"Mayo Clinic. Secondary hypertension. August 9, 2022. https:\/\/www.mayoclinic.org\/diseases-conditions\/secondary-hypertension\/symptoms-causes\/syc-20350679. Accessed Oct 14, 2022."},{"key":"1282_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/IBPC.S223334","volume":"13","author":"MK Pathan","year":"2020","unstructured":"Pathan MK, Cohen DL. Resistant hypertension: where are we now and where do we go from here? Integr Blood Press Control. 2020;13:83\u201393. https:\/\/doi.org\/10.2147\/IBPC.S223334.","journal-title":"Integr Blood Press Control"},{"key":"1282_CR13","doi-asserted-by":"publisher","unstructured":"Doumas M, Imprialos KP, Kallistratos MS, Manolis AJ. Recent advances in understanding and managing resistant\/refractory hypertension. F1000Res. 2020;9:F1000 Facult Rev-169. https:\/\/doi.org\/10.12688\/f1000research.21669.1.","DOI":"10.12688\/f1000research.21669.1"},{"issue":"3","key":"1282_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11906-022-01173-w","volume":"24","author":"LCC Brant","year":"2022","unstructured":"Brant LCC, Passaglia LG, Pinto-Filho MM, de Castilho FM, Ribeiro ALP, Nascimento BR. The burden of resistant hypertension across the world. Curr Hypertens Rep. 2022;24(3):55\u201366. https:\/\/doi.org\/10.1007\/s11906-022-01173-w.","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"1282_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","volume":"73","author":"RM Carey","year":"2019","unstructured":"Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73(2):424\u201331. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.12191.","journal-title":"Hypertension"},{"key":"1282_CR16","unstructured":"Centers for Disease Control and Prevention. NHANES questionnaires, datasets, and related documentation. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/. Accessed June 6, 2023."},{"issue":"4","key":"1282_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/HYPERTENSIONAHA.119.14360.Inthiswork,theauthorsfoundthatamongUSadultstakingantihypertensivemedicationsapproximately40%arebeingprescribedmonotherapy,indicatingphysicianover-relianceonmonotherapies.Additionally,lessthanone-quarterofdrug-treatedhypertensivesintheUSreportedtreatmentwith>2antihypertensivemedications,athresholdfortreatmentintensitytobeconsideredforadiagnosisofresistanthypertension","volume":"75","author":"CG Derington","year":"2020","unstructured":"\u2022 Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005\u20132016. Hypertension. 2020;75(4):973\u201381. \nhttps:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14360. In this work, the authors found that among US adults taking anti hypertensive medications approximately 40% are being prescribed monotherapy, indicating physician over-reliance on monotherapies. Additionally, less than one-quarter of drug-treated hypertensives in the US reported treatment with %3e2 antihypertensive medications, a threshold for treatment intensity to be considered for a diagnosis of resistant hypertension.","journal-title":"Hypertension"},{"key":"1282_CR18","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","volume":"4","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension Nat Rev Dis Primers. 2018;4:18014. https:\/\/doi.org\/10.1038\/nrdp.2018.14.","journal-title":"Hypertension Nat Rev Dis Primers"},{"key":"1282_CR19","volume-title":"Physiology, renin angiotensin system","author":"JH Fountain","year":"2022","unstructured":"Fountain JH, Lappin SL. Physiology, renin angiotensin system. Treasure Island, FL: StatPearls Publishing; 2022."},{"issue":"5","key":"1282_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.semnephrol.2014.08.004","volume":"34","author":"RR Townsend","year":"2014","unstructured":"Townsend RR. Pathogenesis of drug-resistant hypertension. Semin Nephrol. 2014;34(5):506\u201313. https:\/\/doi.org\/10.1016\/j.semnephrol.2014.08.004.","journal-title":"Semin Nephrol"},{"issue":"5","key":"1282_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8241","volume":"12","author":"A Bangash","year":"2020","unstructured":"Bangash A, Wajid F, Poolacherla R, Mim FK, Rutkofsky IH. Obstructive sleep apnea and hypertension: a review of the relationship and pathogenic association. Cureus. 2020;12(5): e8241. https:\/\/doi.org\/10.7759\/cureus.8241.","journal-title":"Cureus"},{"issue":"9","key":"1282_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1161\/CIRCULATIONAHA.115.017923","volume":"133","author":"RC Morris Jr","year":"2016","unstructured":"Morris RC Jr, Schmidlin O, Sebastian A, Tanaka M, Kurtz TW. Vasodysfunction that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt-induced hypertension. Circulation. 2016;133(9):881\u201393. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017923.","journal-title":"Circulation"},{"issue":"6 Pt 2","key":"1282_CR23","doi-asserted-by":"publisher","first-page":"83S","DOI":"10.1016\/s0895-7061(01)02074-x","volume":"14","author":"EL Schiffrin","year":"2001","unstructured":"Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14(6 Pt 2):83S-S89. https:\/\/doi.org\/10.1016\/s0895-7061(01)02074-x.","journal-title":"Am J Hypertens"},{"key":"1282_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/VHRM.S133921","volume":"14","author":"M Correale","year":"2018","unstructured":"Correale M, Ferraretti A, Monaco I, Grazioli D, Di Biase M, Brunetti ND. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Vasc Health Risk Manag. 2018;14:253\u201364. https:\/\/doi.org\/10.2147\/VHRM.S133921.","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"1282_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40262-015-0255-5","volume":"54","author":"PN Sidharta","year":"2015","unstructured":"Sidharta PN, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet. 2015;54(5):457\u201371. https:\/\/doi.org\/10.1007\/s40262-015-0255-5.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1282_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40119-021-00233-7","volume":"10","author":"F Angeli","year":"2021","unstructured":"Angeli F, Verdecchia P, Reboldi G. Aprocitentan, a dual endothelin receptor antagonist under development for the treatment of resistant hypertension. Cardiology and therapy. 2021;10(2):397\u2013406. https:\/\/doi.org\/10.1007\/s40119-021-00233-7.","journal-title":"Cardiology and therapy"},{"issue":"8","key":"1282_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","volume":"16","author":"N Dhaun","year":"2019","unstructured":"Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16(8):491\u2013502. https:\/\/doi.org\/10.1038\/s41569-019-0176-3.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"1282_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1139\/cjpp-2022-0010","volume":"100","author":"M Clozel","year":"2022","unstructured":"Clozel M. Aprocitentan and the endothelin system in resistant hypertension. Can J Physiol Pharmacol. 2022;100(7):573\u201383. https:\/\/doi.org\/10.1139\/cjpp-2022-0010.","journal-title":"Can J Physiol Pharmacol"},{"issue":"10","key":"1282_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","volume":"88","author":"JJ Sim","year":"2013","unstructured":"Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099\u2013107. https:\/\/doi.org\/10.1016\/j.mayocp.2013.06.017.","journal-title":"Mayo Clin Proc"},{"issue":"19","key":"1282_CR30","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.006.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1282_CR31","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1080\/21655979.2021.1933302","volume":"12","author":"C Ma","year":"2021","unstructured":"Ma C, Yan K, Wang Z, Zhang Q, Gao L, Xu T, et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered. 2021;12(1):2187\u2013202. https:\/\/doi.org\/10.1080\/21655979.2021.1933302.","journal-title":"Bioengineered"},{"key":"1282_CR32","doi-asserted-by":"publisher","unstructured":"Aronow WS. Hypertension and cognitive impairment. Ann Transl Med. 2017;5(12):259. https:\/\/doi.org\/10.21037\/atm.2017.03.99.","DOI":"10.21037\/atm.2017.03.99"},{"issue":"1","key":"1282_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12882-019-1315-0","volume":"20","author":"KR Kaczmarski","year":"2019","unstructured":"Kaczmarski KR, Sozio SM, Chen J, Sang Y, Shafi T. Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES). BMC Nephrol. 2019;20(1):138. https:\/\/doi.org\/10.1186\/s12882-019-1315-0.","journal-title":"BMC Nephrol"},{"issue":"5","key":"1282_CR34","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/HYPERTENSIONAHA.114.04276","volume":"64","author":"BM Egan","year":"2014","unstructured":"Egan BM, Li J, Small J, Nietert PJ, Sinopoli A. The growing gap in hypertension control between insured and uninsured adults: National Health and Nutrition Examination Survey 1988 to 2010. Hypertension. 2014;64(5):997\u20131004. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04276.","journal-title":"Hypertension"},{"key":"1282_CR35","doi-asserted-by":"publisher","unstructured":"Kirkland EB, Heincelman M, Bishu KG, Schumann SO, Schreiner A, Axon RN, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003\u20132014. J Am Heart Assoc. 2018;7(11). https:\/\/doi.org\/10.1161\/JAHA.118.008731.","DOI":"10.1161\/JAHA.118.008731"},{"key":"1282_CR36","unstructured":"Smith SM, Ghushchyan V, Libby A. Direct medical expenditures and healthcare utilization associated with resistant hypertension in the United States. Circulation. 2018;130(suppl 2)."},{"issue":"10","key":"1282_CR37","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041. https:\/\/doi.org\/10.1097\/HJH.0000000000001940.","journal-title":"J Hypertens"},{"issue":"1 Suppl 1","key":"1282_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1524-6175.2007.08028.x","volume":"10","author":"WJ Elliott","year":"2008","unstructured":"Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich). 2008;10(1 Suppl 1):20\u20136. https:\/\/doi.org\/10.1111\/j.1524-6175.2007.08028.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"1282_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12913-021-06782-w","volume":"21","author":"A Kataria Golestaneh","year":"2021","unstructured":"Kataria Golestaneh A, Clarke JM, Appelbaum N, Gonzalvez CR, Jose AP, Philip R, et al. The factors influencing clinician use of hypertension guidelines in different resource settings: a qualitative study investigating clinicians\u2019 perspectives and experiences. BMC Health Serv Res. 2021;21(1):767. https:\/\/doi.org\/10.1186\/s12913-021-06782-w.","journal-title":"BMC Health Serv Res"},{"issue":"25","key":"1282_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011121","volume":"97","author":"T Milman","year":"2018","unstructured":"Milman T, Joundi RA, Alotaibi NM, Saposnik G. Clinical inertia in the pharmacological management of hypertension: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(25): e11121. https:\/\/doi.org\/10.1097\/MD.0000000000011121.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"1282_CR41","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1097\/HJH.0b013e32833b4953","volume":"28","author":"J Redon","year":"2010","unstructured":"Redon J, Coca A, Lazaro P, Aguilar MD, Cabanas M, Gil N, et al. Factors associated with therapeutic inertia in hypertension: validation of a predictive model. J Hypertens. 2010;28(8):1770\u20137. https:\/\/doi.org\/10.1097\/HJH.0b013e32833b4953.","journal-title":"J Hypertens"},{"key":"1282_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/HYPERTENSIONAHA.120.16418","volume":"2021","author":"Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD. Hypertension control in the United States","year":"2009","unstructured":"Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD. Hypertension control in the United States. to 2018: factors underlying falling control rates during 2015 to 2018 across age- and race-ethnicity groups. Hypertension. 2009;2021:7.(3):578\u201387.\u00a0https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16418.","journal-title":"Hypertension"},{"issue":"9","key":"1282_CR43","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/HYPERTENSIONAHA.122.19222","volume":"79","author":"P Muntner","year":"2022","unstructured":"Muntner P, Miles MA, Jaeger BC, Hannon L III, Hardy ST, Ostchega Y, et al. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79(9):1971\u201380. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19222.","journal-title":"Hypertension"},{"issue":"4","key":"1282_CR44","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766\u201374. https:\/\/doi.org\/10.1097\/HJH.0b013e32835e2286.","journal-title":"J Hypertens"},{"issue":"3","key":"1282_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40256-021-00510-9","volume":"22","author":"U Ojha","year":"2022","unstructured":"Ojha U, Ruddaraju S, Sabapathy N, Ravindran V, Worapongsatitaya P, Haq J, et al. Current and emerging classes of pharmacological agents for the management of hypertension. Am J Cardiovasc Drugs. 2022;22(3):271\u201385. https:\/\/doi.org\/10.1007\/s40256-021-00510-9.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"1282_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11906-019-0978-z","volume":"21","author":"O Azzam","year":"2019","unstructured":"Azzam O, Kiuchi MG, Ho JK, Matthews VB, Gavidia LML, Nolde JM, et al. New molecules for treating resistant hypertension: a clinical perspective. Curr Hypertens Rep. 2019;21(10):80. https:\/\/doi.org\/10.1007\/s11906-019-0978-z.","journal-title":"Curr Hypertens Rep"},{"key":"1282_CR47","unstructured":"Taylor NP. Breakthrough designations go to renal denervation devices in latest FDA batch. Published December 16, 2020. https:\/\/www.medtechdive.com\/news\/fda-breakthrough-designations-go-to-renal-denervation-devices-in-latest-bat\/592023\/ Accessed Oct 25, 2022."},{"key":"1282_CR48","doi-asserted-by":"publisher","unstructured":"Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2021;11:CD011499. https:\/\/doi.org\/10.1002\/14651858.CD011499.pub3.","DOI":"10.1002\/14651858.CD011499.pub3"},{"key":"1282_CR49","unstructured":"Kandzari DE. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Abstract presented at: American Heart Association Scientific Sessions 2022; November 5\u20137, 2022; Chicago, IL."},{"issue":"10293","key":"1282_CR50","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00788-1.","journal-title":"Lancet"},{"issue":"1","key":"1282_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pcad.2019.12.008","volume":"63","author":"KC Ferdinand","year":"2020","unstructured":"Ferdinand KC, Harrison D, Johnson A. The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension. Prog Cardiovasc Dis. 2020;63(1):64\u201373. https:\/\/doi.org\/10.1016\/j.pcad.2019.12.008.","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"1282_CR52","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1111\/bcp.14825","volume":"87","author":"PG Hunter","year":"2021","unstructured":"Hunter PG, Chapman FA, Dhaun N. Hypertension: Current trends and future perspectives. Br J Clin Pharmacol. 2021;87(10):3721\u201336. https:\/\/doi.org\/10.1111\/bcp.14825.","journal-title":"Br J Clin Pharmacol"},{"key":"1282_CR53","unstructured":"Bakris GL, Blacher J, Ferdinand KC, Persu A, White WB, Balavoine F, et al. Top-line results of the first-in-class aminopeptidase-A inhibitor firibastat in treatment-resistant hypertension (FRESH) study. Presented at: American Heart Association Scientific Sessions 2022; November 5\u20137, 2022; Chicago, IL."},{"issue":"5","key":"1282_CR54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395\u2013445. https:\/\/doi.org\/10.1056\/NEJMoa2213169.","journal-title":"N Engl J Med"},{"issue":"3","key":"1282_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","volume":"128","author":"MY Desai","year":"2013","unstructured":"Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.000849.","journal-title":"Circulation"},{"issue":"3","key":"1282_CR56","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/jpet.118.253864","volume":"368","author":"F Trensz","year":"2019","unstructured":"Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, et al. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther. 2019;368(3):462\u201373. https:\/\/doi.org\/10.1124\/jpet.118.253864.","journal-title":"J Pharmacol Exp Ther"},{"issue":"23","key":"1282_CR57","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Galie","year":"2008","unstructured":"Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.742510.","journal-title":"Circulation"},{"issue":"5","key":"1282_CR58","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","volume":"56","author":"GL Bakris","year":"2010","unstructured":"Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56(5):824\u201330. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.156976.","journal-title":"Hypertension"},{"issue":"7","key":"1282_CR59","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/jch.14517","volume":"24","author":"P Danaietash","year":"2022","unstructured":"Danaietash P, Verweij P, Wang JG, Dresser G, Kantola I, Lawrence MK, et al. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertens (Greenwich). 2022;24(7):804\u201313. https:\/\/doi.org\/10.1111\/jch.14517.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1282_CR60","doi-asserted-by":"publisher","unstructured":"\u2022 Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022. https:\/\/doi.org\/10.1016\/S0140-6736(22)02034-7. In this work, the authors report the results of a recent phase 3 trial evaluating the effectiveness and safety of the dual endothelin receptor antagonist aprocitentan in patients with resistant hypertension. Results showed clinically meaningful blood pressure lowering with aprocitentan in patients with resistant hypertension, associated with manageable adverse effects.","DOI":"10.1016\/S0140-6736(22)02034-7"},{"issue":"3","key":"1282_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320. https:\/\/doi.org\/10.1016\/S2213-8587(15)00417-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1282_CR62","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u20138. https:\/\/doi.org\/10.2337\/dc14-1096.","journal-title":"Diabetes Care"},{"issue":"12","key":"1282_CR63","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/ajh\/hpaa073","volume":"33","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Fitchett D, Ofstad AP, Kraus BJ, Wanner C, Zwiener I, et al. Empagliflozin for patients with presumed resistant hypertension: a post hoc analysis of the EMPA-REG OUTCOME trial. Am J Hypertens. 2020;33(12):1092\u2013101. https:\/\/doi.org\/10.1093\/ajh\/hpaa073.","journal-title":"Am J Hypertens"},{"issue":"1","key":"1282_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jch.12747","volume":"18","author":"RR Townsend","year":"2016","unstructured":"Townsend RR, Machin I, Ren J, Trujillo A, Kawaguchi M, Vijapurkar U, et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich). 2016;18(1):43\u201352. https:\/\/doi.org\/10.1111\/jch.12747.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1282_CR65","unstructured":"Theracos. An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension. ClinicalTrials.gov ID NCT03514641. Last updated: September 21, 2021. https:\/\/clinicaltrials.gov\/study\/NCT03514641. Accessed Sept 22, 2023."},{"issue":"1","key":"1282_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75(1):51\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13569.","journal-title":"Hypertension"},{"issue":"4","key":"1282_CR67","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-019-05062-x","volume":"63","author":"JP Hanrahan","year":"2020","unstructured":"Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020;63(4):733\u201343. https:\/\/doi.org\/10.1007\/s00125-019-05062-x.","journal-title":"Diabetologia"},{"issue":"4","key":"1282_CR68","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1161\/01.HYP.0000239816.13007.c9","volume":"48","author":"JJ Oliver","year":"2006","unstructured":"Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006;48(4):622\u20137. https:\/\/doi.org\/10.1161\/01.HYP.0000239816.13007.c9.","journal-title":"Hypertension"},{"key":"1282_CR69","doi-asserted-by":"publisher","unstructured":"Segal MS, Srinivas TR, Mohandas R, Shuster JJ, Wen X, Whidden E, et al. The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic. J Am Soc Hypertens. 2015;9(8):610\u20139e1. https:\/\/doi.org\/10.1016\/j.jash.2015.05.009.","DOI":"10.1016\/j.jash.2015.05.009"},{"issue":"12","key":"1282_CR70","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.clinthera.2013.10.012","volume":"35","author":"L Almeida","year":"2013","unstructured":"Almeida L, Nunes T, Costa R, Rocha JF, Vaz-da-Silva M, Soares-da-Silva P. Etamicastat, a novel dopamine beta-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. Clin Ther. 2013;35(12):1983\u201396. https:\/\/doi.org\/10.1016\/j.clinthera.2013.10.012.","journal-title":"Clin Ther"},{"key":"1282_CR71","unstructured":"Oslo University Hospital. Nesiritide in Hypertension (TENSE1). ClinicalTrials.gov ID NCT02608996. Last updated: January 3, 2018. https:\/\/clinicaltrials.gov\/study\/NCT02608996. Accessed Sept 22, 2023."},{"issue":"3","key":"1282_CR72","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2208391.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-023-01282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-023-01282-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-023-01282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:28:29Z","timestamp":1717568909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-023-01282-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1007\/s11906-023-01282-0","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"27 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"JMF has received payment for a lecture at a continuing medical education event from Janssen; research funding from Astra Zeneca, Mineralys Therapeutics, SoniVie, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Idorsia, Novartis, Quantam Genomics, ReCor Medical, and Vascular Dynamics; and served as a consultant for Ardelyx, Teva Pharmaceuticals, Amgen, ReCor Medical, Fibrogen, Janssen, and the American College of Physicians Board of Regents. MGB has no conflicts of interest to disclose KTM is an employee of Janssen Pharmaceuticals, Inc. and may own stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}